Status not kept up to date
Robot-assisted IVOR-LEWIS Esophagectomy
NCT03140189 · Ruijin Hospital · Updated 19 Jan 2022
- What is being tested
- Not stated
- For
- Clinical or Oncologic Benefits of Robot-assisted IVOR-LEWIS in Esophageal Cancer
- Kind of study
- Watches patients without assigning a treatment. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 51 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 14 June 2017, ends 4 April 2024. Registered 4 May 2017.
- Results
- None posted yet.
In the researchers' words
Minimally invasive esophagectomy (MIE) have become increasingly popular in esophageal cancer. It is generally accepted that comparing to open resections, MIE results in decreased postoperative pain, faster recovery times, and shorter hospital stays with comparable oncologic outcomes. However, MIE poses an important challenge for established thoracic surgeons as it is a difficult technique to become skilled at with an protracted learning curve. Standard laparoscopic and thoracoscopic instruments are rigid and provide a finite freedom of movement with a two dimensional visualization of the operating field. Such a difficulty is increased even more when the Ivor-Lewis esophagectomy with an intrathoracic anastomosis is needed. Robot- assisted surgical system has opened a new era of minimally invasive surgery. Robot- assisted surgery offers some advantages including high- definition three- dimensional visualization and 7 degrees of freedom with the use of its surgical wrists, motion scaling, and tremor filtration, allowing the surgeon to perform complex operations comfortably in the domain of urinary tract, hepatobiliary and gynecological surgery. Although a robot-assisted thoraco- laparoscopic minimally invasive esophagectomy (RAMIE) was initiated from 2003, the published experience with RAMIE remains small, especially for Ivor- Lewis approaches. The aim of this study was to…
Sites
- Yajie ZhangShanghai, China
